Compare GPK & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPK | BEAM |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | United States | United States |
| Employees | 23000 | N/A |
| Industry | Containers/Packaging | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.0B |
| IPO Year | 2007 | 2019 |
| Metric | GPK | BEAM |
|---|---|---|
| Price | $9.57 | $29.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $13.08 | ★ $50.75 |
| AVG Volume (30 Days) | ★ 5.5M | 2.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.53% | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $8,617,000,000.00 | $24,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | $33.77 |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $8.79 | $15.52 |
| 52 Week High | $23.76 | $36.44 |
| Indicator | GPK | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 53.99 |
| Support Level | $9.17 | $25.36 |
| Resistance Level | $10.02 | $32.01 |
| Average True Range (ATR) | 0.35 | 1.94 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 45.98 | 53.51 |
Graphic Packaging Holding Co is a holding company that manufactures and sells a variety of paper-based consumer packaging products through its subsidiaries. The company's reportable segments are; Americas Paperboard Packaging, and International Paperboard Packaging. The majority of the revenue is generated from its Americas Paperboard Packaging segment which includes paperboard packaging sold predominantly to consumer packaged goods (CPG) companies and cups, lids and food containers sold to foodservice companies and quick-service restaurants (QSR) serving the food, beverage, and consumer product markets in the Americas. Geographically, the company operates in Americas, Europe and Asia Pacific regions.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.